Shan Ahmed Khan

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

ASX Top Gainers Today: Immutep, Cosmo Metals, OD6 & Sunrise Energy Metals Lead the Rally (9 December 2025)

ASX Top Gainers Today: Immutep, Cosmo Metals, OD6 & Sunrise Energy Metals Lead the Rally (9 December 2025)

The S&P/ASX 200 spent Tuesday morning drifting slightly lower, extending a pattern of tight trading ranges as investors waited on the Reserve Bank of Australia’s final interest rate decision for 2025. By late morning, the benchmark was down around 0.1%–0.2%, with breadth skewed to the downside and weakness in energy, gold and parts of tech offset by pockets of strength in resources and healthcare. Market Index+1
9 December 2025
·····
Best Stocks to Buy Now on the Australian Stock Market (ASX) – December 2025 Guide

Best Stocks to Buy Now on the Australian Stock Market (ASX) – December 2025 Guide

Australia’s sharemarket is in an odd mood right now: the S&P/ASX 200 is hovering in the mid‑8500s after several sessions of flat, slightly negative trading, as investors wait for the next move from the Reserve Bank of Australia.The Australian+1Beneath that sleepy headline index, though, you’ve got big rotations: materials are up more than 26% year to date and leading every other sector, while the heavyweight financials have recently suffered one of their worst months since 2022.Livewire Markets+1
9 December 2025
Fluence Energy (FLNC) Stock Today: Downgrades Hit High-Flying Battery Storage Play – Latest News, Price Targets and Forecasts

Fluence Energy (FLNC) Stock Today: Downgrades Hit High-Flying Battery Storage Play – Latest News, Price Targets and Forecasts

After a huge rally over the past two weeks, the grid‑scale battery and software specialist is trading around $22–23 per share, down roughly 7–8% intraday as fresh analyst downgrades collide with strong growth guidance and a new UK battery storage milestone. The stock is still up more than 30% year‑to‑date and sits close to its one‑year high in the mid‑$20s, after climbing from a 12‑month low near $3.50. Finviz+1
8 December 2025
··
Air Products Stock Plunges to 52‑Week Low on Yara Hydrogen Deal – What It Means for APD Investors Now

Air Products Stock Plunges to 52‑Week Low on Yara Hydrogen Deal – What It Means for APD Investors Now

Air Products and Chemicals, Inc. just had a rough session.On December 8, 2025, the stock dropped roughly 9–10%, hit a new 52‑week low around $235–236, and briefly became the worst performer in the S&P 500 after the company announced advanced partnership talks with Yara International on major low‑emission ammonia projects in the U.S. and Saudi Arabia. MarketScreener+1
8 December 2025
··
Legend Biotech (LEGN) Stock Hits 52‑Week Low After UBS Cut: December 8, 2025 News, Outlook and Forecast

Legend Biotech (LEGN) Stock Hits 52‑Week Low After UBS Cut: December 8, 2025 News, Outlook and Forecast

Legend Biotech Corp. shares are under heavy pressure on December 8, 2025, trading in the mid‑$20s and touching a new 52‑week low around $25.66 during the session. The slide comes despite strong clinical momentum for its flagship CAR‑T therapy CARVYKTI® and robust revenue growth, as investors react to valuation resets and ongoing concerns about profitability and cash flow. Investing.com+1
8 December 2025
··
Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals, Inc. is finishing 2025 with the kind of momentum small-molecule biotechs daydream about. On 8 December 2025, the RNA interference specialist climbed to a new 52‑week high near $69 per share after the company announced it had dosed the first subjects in its Alzheimer’s disease trial ARO‑MAPT and highlighted a string of recent FDA victories and deal-driven cash inflows. Arrowhead Pharmaceuticals, Inc.+2MarketBeat+2
8 December 2025
·
Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025

Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025

Nurix Therapeutics, Inc. is back in the spotlight. On December 8, 2025, the biotech stock surged roughly 20% intraday after the company released new Phase 1 data for its Bruton’s tyrosine kinase degrader bexobrutideg in blood cancers at the American Society of Hematology Annual Meeting and scheduled a corporate webcast for this evening. MarketBeat+3GlobeNewswire+3GlobeNewswire+3
8 December 2025
··
Carvana (CVNA) Soars on S&P 500 Inclusion: Latest News, Stock Forecast and Analysis as of December 8, 2025

Carvana (CVNA) Soars on S&P 500 Inclusion: Latest News, Stock Forecast and Analysis as of December 8, 2025

Carvana Co. is back in the spotlight. On Monday, December 8, 2025, the online used-car retailer’s shares surged again after S&P Dow Jones Indices confirmed that Carvana will join the benchmark S&P 500 index on December 22, 2025. The stock traded around $454 in late session, up roughly 14% on the day and near record highs, capping a year in which the stock has gained well over 100% and staged one of the most dramatic recoveries in recent market history. Reuters
8 December 2025
··
Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough – What the New Data and Wall Street Forecasts Signal

Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough – What the New Data and Wall Street Forecasts Signal

Wave Life Sciences Ltd. staged a spectacular rally on Monday after unveiling positive interim data from its Phase 1 INLIGHT trial for obesity drug candidate WVE‑007. Shares surged from a close of $7.49 on Friday, December 5 to intraday levels around $17–18, a gain in the range of 120%–140% and a new multi‑year high. Yahoo Finance+2Investing.com+2
8 December 2025
·
1 … 527 528 529 530 531 … 608

Google Preferred Source

Follow on Google News
Add as preferred source Open in Google News

Stock Market Today